In October, due to demand from existing healthcare partners, CTS began testing blood donors for antibody to Babesia microti under an Investigational New Drug exemption as a release test.
In January, CTS is incorporated as a non-profit organization owned by Vitalant and OneBlood (formerl...
CTS Tampa lab implemented the Ortho Clinical Diagnostics VITROS® testing platform to perform COVID-1...
In April, CTS becomes the first blood donor testing organization in the US to implement Zika testing...
In August, the CTS Tampa lab transitioned to the same laboratory information systems (LIS) as the Da...
Transitioned all 5 CTS labs from an investigational new drug (IND) to a licensed pooled Babesia test...
In 2016, CTS tested more source plasma samples (4.9 million) than blood donor samples (4.5 million).